Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of lyophilized RSV mRNA vaccine in adults aged 50 years and older
CTR20253567Phase 2Active
- Sponsor
- Abogen Bioscience
- Start
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ABO1105B in respiratory syncytial virus disease (RSV), pulmonary infection, sponsored by Abogen Bioscience. Started Sep 2025; status: active.
02
Drugs
ABO1105B
03
Conditions
respiratory syncytial virus disease (RSV)pulmonary infection
Beyond the preview
Go deeper on CTR20253567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253567.